NCT04885855View on ClinicalTrials.gov

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

December 29, 2023

Study Completion Date

March 15, 2024

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir 400 MG

Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)

DRUG

Ravidasvir 200mg

Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)

Trial Locations (1)

05460

Hospital Sultanah Bahiyah, Alor Star

All Listed Sponsors
lead

Muhammad Radzi Abu Hassan

OTHER_GOV

NCT04885855 - 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C | Biotech Hunter | Biotech Hunter